Secondary hyperparathyroidism develops in CKD due to a combination of vitamin D
deficiency, hypocalcemia, and hyperphosphatemia, and it exists in nearly all patients at the …

Calcium, phosphorus, and magnesium homeostasis is altered in chronic kidney disease
(CKD). Hypocalcemia, hyperphosphatemia, and hypermagnesemia are not seen until …

CKD and CKD-related mineral and bone disorders (CKD-MBDs) are associated with high
cardiovascular and mortality risks. In randomized clinical trials (RCTs), no single drug …

Introduction: Extended-release calcifediol (ERC) is an orally administered prohormone of
active vitamin D (1, 25-dihydroxyvitamin D [1, 25D]) designed to safely and sufficiently …

OBJECTIVE: The data on the treatment of secondary hyperparathyroidism (SHPT) provided
in scientific publications are divergent and contradictory. Therefore, the aim of our systematic …

Until the discovery of calcimimetics, the management of secondary hyperparathyroidism
(SHPT) relied exclusively on treatment with phosphate binders, vitamin D derivatives or …

Purpose The present systematic review and meta-analysis was designed to evaluate the
efficacy and safety of microwave ablation (MWA) treatment for secondary …

Background Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Background Secondary hyperparathyroidism (SHPT) is a common complication of chronic
kidney disease (CKD). Cinacalcet use is controversial in non-dialysis patients. Methods This …

Excessive secretion of parathyroid hormone-related protein (PTHrP) by tumors stimulates
bone resorption and increases renal tubular reabsorption of calcium, resulting in …